Current experience with 5-HT3 receptor antagonists in fibromyalgia

Rheumatic Disease Clinics of North America

Volumn 28, Issue 2, 2002, Pages 319-328

  Späth, Michael ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GRANISETRON; HYDRODOLASETRON; ONDANSETRON; PLACEBO; RECEPTOR SUBTYPE; SEROTONIN; SEROTONIN 3 ANTAGONIST; SEROTONIN 3 RECEPTOR; SEROTONIN AGONIST; SEROTONIN RECEPTOR; SUBSTANCE P; TROPISETRON; SEROTONIN ANTAGONIST;

ADULT; AGED; BRAIN; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RECEPTOR BINDING; FEMALE; FIBROMYALGIA; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART ARRHYTHMIA; HORMONE RELEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR MECHANICS; MULTICENTER STUDY; NEUROMODULATION; NEUROTRANSMITTER RELEASE; NOCICEPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR DENSITY; RECEPTOR UPREGULATION; REVIEW; SEROTONIN RELEASE; SPINAL CORD; PATHOPHYSIOLOGY; PHYSIOLOGY;

FIBROMYALGIA; HUMAN; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS; HUMANS; RECEPTORS, SEROTONIN, 5-HT3;

EID: 0035990336     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-857X(01)00014-X     Document Type: Review

References (67)

1. Advances in fibromyalgia: Possible role for central neurochemicals
2. Disordered growth hormone secretion in fibromyalgia: A review of recent findings and a hypothesized etiology
3. A randomized, double-blind, placebo-controlled study of growth hormone in the treatment of fibromyalgia
4. Hypothalamic-pituitary-insulin-like growth factor-I axis dysfunction in patients with fibromyalgia
5. Abnormal brain regional cerebral blood flow (rCBF) and cerebrospinal fluid (CSF) levels of substance P (SP) in patients and non-patients with fibromyalgia (FM)
6. Neurohormonal perturbations in fibromyalgia
7. 31P magnetic resonance spectroscopy of skeletal muscle in patients with fibromyalgia
8. Hyperalgesia mediated by spinal glutamate or substance P receptor blocked by spinal cyclooxygenase inhibition
9. Neurobiological concepts of fibromyalgia - The possible role of descending spinal tracts
10. Neuroendocrine perturbations in fibromyalgia and chronic fatigue syndrome
11. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome
12. Learning and memory in pain pathways
13. Cerebrospinal fluid levels of beta-endorphin in patients with fibromyalgia (fibrositis syndrome)
14. Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: New features for diagnosis
15. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin)
16. 5-HT receptor classification and nomenclature: Towards a harmonization with the human genome
17. Preclinical and clinical pharmacology of the 5-HT3 receptor antagonists
18. The distribution of specific binding of the 5-HT3 receptor ligand [3H]GR65630 in rat brain using quantitative autoradiography
19. Identification and distribution of 5-HT3 receptors in rat brain using radioligand binding
20. Identification and distribution of 5-HT3 recognition sites in the rat gastrointestinal tract
21. Nervous system distribution of the serotonin 5-HT3 receptor mRNA
22. Spinal 5-HT3 receptor-mediated antinociception: Possible release of GABA
23. The role of 5HT3 in nociceptive processing in the rat spinal cord: Results from behavioural and electrophysiological studies
24. 5-HT in nervous system disease and migraine
25. Antinociceptive effects of intrathecally administered 2-methylserotonin in developing rats
26. Topical ondansetron attenuates nociceptive and inflammatory effects of intradermal capsaicin in humans
27. 5-HT3 receptors modulate spinal nociceptive reflexes
28. Reversal of the antinociceptive effects of intrathecally administered serotonin in the rat by a selective 5-HT3 receptor antagonist
29. Serotonin and nociception
30. Peripherally administered serotonin 5-HT3 receptor antagonists reduce inflammatory pain in rats
31. Treatment of diarrhea in carcinoid syndrome with ondansetron, tropisetron, and clonidine
32. A randomized double-blind placebo-controlled study of tropisetron in the treatment of outpatients with generalized anxiety disorder
33. Psychosis in advanced Parkinson's disease: Treatment with ondansetron, a 5-HT3 receptor antagonist
34. Serotonin and alcohol drinking
35. Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence
36. 5-HT3 antagonists and disorders of cognition
37. Ondansetron pretreatment to alleviate pain on propofol injection: A randomized, controlled, double-blinded study
38. Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugs
39. 5-HT3 receptor antagonists inhibit sensory neuropeptide release from the rat spinal cord
40. Serotonin unmasks functional NK-2 receptors in vagal sensory neurones of the guinea-pig
41. Morphine, 5-HT2 and 5-HT3 receptor antagonists reduce c-fos expression in the trigeminal nuclear complex following noxious chemical stimulation of the rat nasal mucosa
42. Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: A randomized, placebo-controlled, double-blind cross-over trial
43. Efficacy of ICS 205-930, a novel 5-hydroxytryptamine3 (5-HT3) receptor antagonist, in the prevention of migraine attacks. A complex answer to a simple question
44. 5-HT1C receptor activation: A key step in the initiation of migraine?
45. 5-Hydroxytryptamine (5-HT) and the initiation of migraine: New perspectives
46. Evidence of a central antinociceptive effect of paracetamol involving spinal 5HT3 receptors
47. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee
48. Efficacy and tolerability of tropisetron in primary fibromyalgia - A highly selective and competitive 5-HT3 receptor antagonist
49. Ondansetron in the treatment of anxiety
50. Treatment of fibromyalgia with tropisetron, a 5HT3 serotonin antagonist: A pilot study
51. Oral treatment of fibromyalgia with tropisetron given over 28 days: Influence on functional and vegetative symptoms, psychometric parameters and pain
52. Treatment of chronic fatigue syndrome with 5-HT3 receptor antagonists - Preliminary results
53. Do predictors exist for the therapeutic effect of 5-HT3 receptor antagonists in fibromyalgia?
54. Effect of tropisetron on circulating catecholamines and other putative biochemical markers in serum of patients with fibromyalgia
55. Results of the intravenous administration of tropisetron in fibromyalgia patients
56. Fibromyalgia treatment with intravenous tropisetron administration
57. Neuropharmacological dissection of placebo analgesia: Expectation-activated opioid systems versus conditioning-activated specific subsystems
58. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: Practical issues and specific cases
59. Response expectancies in placebo analgesia and their clinical relevance
60. Placebos, drug effects, and study design: A clinician's guide
61. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: Ethical and scientific issues
62. Modulation of nociception by descending serotoninergic projections
63. Possible mechanisms for ischemic colitis during alosetron therapy
64. Effects of alosetron on spontaneous migrating motor complexes in murine small and large bowel in vitro
65. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome
66. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome
67. Gender-related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome